https://ntp.niehs.nih.gov/go/n463406

Target Organs and Levels of Evidence for TR-604

Toxicology and Carcinogenesis Studies of Triclosan (CASRN 3380-34-5) Administered Dermally to B6C3F1/N Mice

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Triclosan
3380-34-5		 11/01/2022 Dermal Administration
[Untreated control group], 0, 1.25, 2.7, 5.8, or 12.5 mg/kg/day		 National Center for Toxicological Research

Levels of Evidence

Male Mice: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: hepatocellular adenoma ([26/48], 25/48, 30/48, 34/48, 31/48, 26/48); hepatocellular carcinoma ([27/48], 15/48, 17/48, 20/48, 25/48, 27/48); hepatocellular adenoma or carcinoma (combined) ([41/48], 31/48, 35/48, 40/48, 42/48, 40/48)
Non-Neoplastic Lesions
  • Skin, site of application: epidermis, hyperplasia; epidermis, inflammation, suppurative; epidermis, ulcer
Female Mice: Equivocal Evidence
Type Organ/Tissue (Lesion)
May Have Been Related
  • Pancreas: islets, adenoma ([0/48], 1/48, 0/48, 0/48, 0/48, 3/48)
Non-Neoplastic Lesions
  • Skin, site of application: epidermis, hyperplasia